Shares in Innate Pharma plunged near 50 percent on Thursday after it said that a combination of lirilumab and Bristol-Myers Squibb’s PD-1 inhibitor Opdivo failed to provide clear evidence of benefit in patients with squamous cell carcinoma of the head and neck.
Janssen has announced the launch of Tremfya in the UK for adults with moderate to severe plaque psoriasis, following a green light from European regulators.
Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia.
Online GP consultation systems “may not be the silver bullet for reducing GP workload and patient waiting times that government policymakers are hoping for,” according to University of Bristol researchers.
Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
NHS figures have revealed a significant drop in the number of GPs in England in the last year despite government pledges to swell the workforce.
The Medicines Healthcare products Regulatory Agency has launched a social media campaign to encourage the reporting of suspected side effects from over-the-counter medicines.
Chancellor Philip Hammond’s Autumn Budget has promised an extra £2.8 billion for NHS services over the next three years, though the amount falls well short of the £4 billion deemed by health leaders as necessary to retain the current quality of services.
GlaxoSmithKline and Innoviva have submitted new data to regulators in the US in support of expanding the label of Trelegy Ellipta in chronic obstructive pulmonary disease.
NHS England has named eleven new projects chosen for the latest round of an initiative to develop and spread ideas, equipment and technology that can potentially save lives and money.
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The UK’s Competition and Markets Authority has provisionally ruled that Concordia abused its dominant position to overcharge the NHS by millions of pounds for an essential thyroid drug.
ViiV Healthcare and Janssen’s Juluca has been green lighted in the US as the first two-drug regimen for some patients with HIV.
US biotech Acorda Therapeutics is discontinuing development of its experimental Parkinson’s disease therapy tozadenant on concerns over patient safety.
NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
